Triple Negative Clinical Trials

1 recruiting

Triple Negative Trials at a Glance

25 actively recruiting trials for triple negative are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Phase 2 with 15 trials, with the heaviest enrollment activity in Nashville, Houston, and Toronto. Lead sponsors running triple negative studies include M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC, and Universitaire Ziekenhuizen KU Leuven.

Browse triple negative trials by phase

Treatments under study

About Triple Negative Clinical Trials

Looking for clinical trials for Triple Negative? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Triple Negative trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Triple Negative clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Not Applicable

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Melanoma (Skin Cancer)Renal Cell Carcinoma (Kidney Cancer)Breast Cancer (Triple Negative Breast Cancer (TNBC))
Jessica Mezzanotte Sharpe25 enrolled1 locationNCT07555210
Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled257 locationsNCT06841354
Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled268 locationsNCT06966700
Recruiting
Not Applicable

Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC

Aerobic ExerciseEarly Stage Triple Negative Breast Cancer
M.D. Anderson Cancer Center33 enrolled1 locationNCT07216495
Recruiting
Phase 2

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Triple Negative Breast Neoplasms
Universitaire Ziekenhuizen KU Leuven53 enrolled6 locationsNCT06365788
Recruiting
Phase 2

LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC), Early Setting
Universitaire Ziekenhuizen KU Leuven356 enrolled10 locationsNCT06831955
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1Phase 2

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

BreastCancerMetastatic+2 more
University of Southern California65 enrolled3 locationsNCT04333706
Recruiting
Phase 1

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc.70 enrolled8 locationsNCT02926690
Recruiting
Phase 2

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

Breast CancerBreast Cancer Stage IIBreast Cancer Invasive+2 more
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's40 enrolled2 locationsNCT07188246
Recruiting
Not Applicable

The TASTY-steering Study

Metastatic Triple Negative Breast Cancer or Metastatic Testicular Cancer, or Stage II-IV Diffuse Large B Cell Lymphoma
University Medical Center Groningen201 enrolled11 locationsNCT07258563
Recruiting
Phase 2

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Triple Negative Breast Cancer MetastaticMelanoma MetastaticColorectal Cancer Metastatic
Fudan University95 enrolled1 locationNCT06889610
Recruiting
Phase 2

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

Triple Negative Breast Neoplasms
UNICANCER220 enrolled20 locationsNCT05973864
Recruiting
Phase 2

IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

Metastatic Endocrine RefractoryTriple Negative Invasive Lobular Carcinoma
M.D. Anderson Cancer Center29 enrolled1 locationNCT07229417
Recruiting
Phase 1

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Gastric CancerCervical CancerCancer+7 more
Rondo Therapeutics149 enrolled2 locationsNCT07218003
Recruiting
Phase 1Phase 2

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Triple Negative Locally Advanced Non-resectable Breast Cancer
Marengo Therapeutics, Inc.50 enrolled8 locationsNCT06827613
Recruiting
Phase 2

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Triple Negative Breast Cancer Metastatic
IFOM ETS - The AIRC Institute of Molecular Oncology37 enrolled6 locationsNCT05582538
Recruiting
Phase 1Phase 2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Advanced Refractory Solid TumorsAdvanced Triple Negative Breast CancersMetastatic Triple Negative Breast Cancers
National University Hospital, Singapore63 enrolled1 locationNCT05035745
Recruiting

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Breast Cancer Stage IIBreast Cancer InvasiveBreast Cancer Stage III+1 more
Emory University10 enrolled1 locationNCT05877859
Recruiting
Early Phase 1

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

TNBC - Triple-Negative Breast CancerLocally Advanced Triple Negative Breast Cancer
Rima Patel15 enrolled1 locationNCT06637306